Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free latanoprost versus Xalatan in open-angle glaucoma or ocular hypertension
2015-005314-29Phase 3Terminated
- Sponsor
- OmniVision
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by OmniVision. Primary endpoint: Change in diurnal intraocular pressure from baseline to last visit. Started Jan 2016; status: terminated.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2015-005314-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005314-29.